Skip to main content
Daniel Persky, MD, Oncology, Tucson, AZ

Daniel Oscar Persky MD

Hematologic Oncology


Professor of Medicine, University of Arizona College of Medicine

Join to View Full Profile
  • 3838 N Campbell AveTucson, AZ 85719

  • Phone+1 520-694-2873

  • Fax+1 520-694-0848

Dr. Persky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2000 - 2003
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 2000
  • Harvard University
    Harvard UniversityAB, Biochemical Sciences, Magna Cum Laude, 1992 - 1996

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 2002 - 2025
  • CT State Medical License
    CT State Medical License 2012 - 2014
  • NY State Medical License
    NY State Medical License 2003 - 2006
  • MN State Medical License
    MN State Medical License 2001 - 2003
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma (L-NN-MCL) with P53 Gene Re-arrangement/Mutation Is Highly Responsive to Rituximab/Ibrutinib Combination Therapy  
    Shahram Mori, Juan Varela, Steven C Goldstein, Daniel O Persky, Clinical Lymphoma, Myeloma, & Leukemia
  • Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/vincristine in Relapsed/refractory Aggressive B-cell Lymphoma  
    Daniel Persky, Soham Puvvada, Catherine Spier, Gregory Monohan, Ari VanderWalde, Daruka Mahadevan, Clinical Cancer Research

Abstracts/Posters

  • Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
    Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

  • Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma (L-NN-MCL) with P53 Gene Re-arrangement/Mutation Is Highly Responsive to Rituximab/Ibrutinib Combination TherapyNovember 2018

Press Mentions

  • Clinical Challenges: Using MRD in Chronic Lymphocytic Leukemia Management
    Clinical Challenges: Using MRD in Chronic Lymphocytic Leukemia ManagementDecember 22nd, 2021
  • Many Non-Hodgkin's Lymphoma Patients Can Skip Radiation, Collaborative Study Finds
    Many Non-Hodgkin's Lymphoma Patients Can Skip Radiation, Collaborative Study FindsOctober 6th, 2020
  • Study: Most with Early DLBCL Can Skip RT
    Study: Most with Early DLBCL Can Skip RTDecember 9th, 2019

Grant Support

  • 2014 Cancer Clinical Investigator Team Leadership AwardNCIPresent

Committees

  • Member, SWOG Lymphoma Working Committee

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: